Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858585/
https://www.ncbi.nlm.nih.gov/pubmed/26837842
http://dx.doi.org/10.1038/leu.2016.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858585/
https://www.ncbi.nlm.nih.gov/pubmed/26837842
http://dx.doi.org/10.1038/leu.2016.5

Ejemplares similares